Montelucaste Tolife (Montelukast Sodium)

Montelukast, the active ingredient in Montelucaste Tolife, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as prescribed.

GNH USA supplies Montelucaste Tolife as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelucaste Tolife is a leukotriene receptor antagonist used in respiratory and allergic disorders.

- Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelucaste Tolife may cause a range of adverse reactions.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema or anaphylaxis - Neuropsychiatric events including mood changes, depression or suicidal thoughts - Elevated liver enzymes - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe bronchospasm

Before prescribing Montelucaste Tolife, clinicians should consider several safety aspects.

- Assess asthma control: ensure patient is on appropriate baseline therapy. - Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. - Use caution in hepatic impairment: dose adjustment may be needed. - Avoid in patients with known hypersensitivity to montelukast or tablet excipients. - Review concomitant medications for potential interactions. - Store at room temperature: keep in the original pack, protect from moisture.

Montelucaste Tolife can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin) may lower montelukast plasma levels. - Phenobarbital can reduce therapeutic effect. - Co‑administration with other leukotriene modifiers (e.g., zafirlukast) may increase side‑effect risk.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs) may heighten neuropsychiatric adverse events. - Azole antifungals (ketoconazole) can raise montelukast concentrations. - Warfarin may experience altered INR values. - Beta‑agonists may produce additive bronchodilation. - NSAIDs may increase gastrointestinal irritation.